October #40 : Drug Bust - by Gabi Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Open Wide, AIDS Ride

Climb Every Mountain

The Necessity of Excess

The Latest on Early Intervention

Photo Copy

Tomorrow's "It" Girl

Post-Gay Poster Guy


To the Editor

Bazaar Science

Drug Bust

News Ruse

Standard Issue

The New Reality

Say What

Life After HIV

Pot for Thought

Micro Softee

World Cup: Europe vs. US

Summer Camp

A Colder War

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

October 1998

Drug Bust

by Gabi Horn

Marked-down meds for Third World

Baby-stepping toward “bridging the treatment gap” —the mantra at July’s 12th World AIDS Conference—several companies, including Glaxo Wellcome, Abbott Labs and Bristol-Myers Squibb, announced drug price cuts of up to 75 percent in the developing world, home to more than 90 percent of the world’s 30.6 million HIVers. As part of the hotly debated UNAIDS HIV Drug Access Initiative, discount drugs were shuttled south in June to Uganda and the Ivory Coast.

But Merck bailed from the price-slashing ship. “To bring sophisticated therapies—Crixivan specifically, which must be stored at low humidity—to countries where there may not be fresh water could engender drug resistance,” said spokesperson Jeff Sturchio. “That would be worse than doing nothing.”

The HIV Human Rights Project’s Eric Sawyer, who helped draft the initiative, doesn’t buy Merck’s message. “If inadequate medical infrastructure is the reason Merck isn’t participating, that’s baseless,” he said, pointing to the rigorous prerequisites participating countries must meet. “Crixivan is difficult to comply with,” Sawyer conceded, “but Merck underestimates the developing world and UNAIDS.” Angry ACT UPers defaced Merck’s booth at Geneva, stating it “has no right participating in a conference entitled ‘Bridging the Gap.’”

Slow down, cautioned Linda Meredith, a medical marketing consultant and activist. “Are developing nations really best served with triple-combination therapy? So often there’s little thought given to what’s needed. Instead, stakes get set in the ground and everyone scrambles to ante up.”

Even marked-down meds are out of most PWAs’ reach. For Ugandans, who typically earn $500 a month, Glaxo’s $200-a-month Combivir (at 60 percent off) is likely too pricey.  

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.